List of Implants Companies in Israel - 9

BlueWind Medical is a medical device company that aims to transform Neurostimulation therapy. Founded in 2010 by the Rainbow Medical Group, BlueWind Medical has successfully completed several clinical studies and is focused on bringing this breakthroughRENOVA™ neuromodulation device for the treatment of Overactive Bladder to the market.

CartiHeal, a privately-held medical device company with headquarters in Israel, develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints. CartiHeal’s cell-free, off-the-shelf implant is CE marked for use in cartilage and osteochondral defects. Agili-C has been implanted in over 400 patients with cartilage lesions in the knee, ankle and great toe in a series of trials conducted in leading centers in Europe and Israel. In these trials, the implant was used to treat a broad spectrum of cartilage lesions, from single focal lesions to multiple and large defects in patients suffering from osteoarthritis. In the United States the Agili-C implant is not available for sale - it is an investigational device limited for use in the IDE study.

The NEXUS® Aortic Arch Stent Graft System by Endospan is the only CE-approved off-the-shelf branched endovascular aortic arch system. Indicated for wide range of aortic pathologies, including arch aneurysms, thoracic dissections, and PAU, NEXUS® is designed to overcome the specific challenges of the aortic arch anatomy. The NEXUS® "Dock and Lock" modular system provides stable and secured anatomical anchoring and atraumatic sealing in a wide range of anatomies. Privately held Endospan, headquartered in Herzlia (Tel Aviv), Israel, is a pioneer in the endovascular repair of aortic arch disease including aneurysms and dissections. Endospan's NEXUS® Aortic Arch Stent Graft System is the first endovascular off-the-shelf system with CE Mark to treat a greatly underserved group of patients diagnosed with a dilative lesion in, or near the aortic arch. While minimally invasive endovascular repair has been the standard of care for Abdominal Aortic Aneurysm (AAA), Aortic Arch Disease patients with aneurysms or dissections have not been as fortunate and have had little choice but to undergo open-chest surgery with its invasiveness and risks, lengthy hospitalization periods, and prolonged recuperation. For additional information about Endospan, visit their website at www.endospan.com.

Magenta is developing miniaturized catheter-mounted axial flow-pumps for mechanical circulatory support indications, based on Magenta's core technology of self-expanding impellers and pump heads. Our percutaneous Left Ventricular Assist Device (pLVAD) is a next-generation low-profile arterial pump, intended for temporary support of patients undergoing high-risk coronary interventions and the treatment of patients admitted with cardiogenic shock.

Pi-Cardia is a medical device company and market leader in the development of a broad portfolio of leaflet modification solutions for treating heart valves. The company has years of knowledge and expertise accumulated in degenerated valves, including calcification patterns, mode of valve failure, and impact of various methods of leaflet modification. ShortCut™ is designed to provide a safe, simple, and effective way to split leaflets of a pre-existing valve to enable TAVR in patients at risk for coronary obstruction and may assist in preserving coronary access.

Premia Spine is a medical technology company based in Netanya, Israel, founded in March 2011 by Ron Sacher. The company specializes in developing innovative spinal implants aimed at improving patient outcomes. Premia Spine focuses on providing alternatives to traditional spinal fusion surgeries through minimally invasive procedures that help preserve spinal flexibility and reduce pain. The company offers a range of spinal implant systems, including the TOPS™ System, which treats spinal stenosis and spondylolisthesis while allowing for natural motion and providing pain relief. Other products include the ProMIS™ System and Nexux™ Systems, designed for treating back and leg pain through minimally invasive techniques. Premia Spine also provides training and clinical support for healthcare providers to ensure effective integration of its products into treatment protocols. With a commitment to advancing spinal care, Premia Spine has filed 20 patents and raised $7 million in funding, focusing on orthopedic and neurosurgical innovations.

Pronto Diagnostics is a leading provider of molecular diagnostic products and services, with extensive knowledge, experience and R&D capabilities in genetic analysis. ProntoLab™, Pronto's molecular services laboratory, has accreditation from the Israel Ministry of Health and ISO 9001:2008 certification. It provides both clinical diagnostics and clinical research services, which include DNA purification; sequencing and deletion/duplication analysis for any gene; fragment analysis; pharmacogenetic testing and epigenetic tests. ProntoLab™ carries out sequencing and data analysis of whole-exome, as well targeted gene panels for specific diseases and syndromes. Pronto Diagnostics has been granted exclusive distribution rights in Israel from leading international molecular diagnostic companies to high quality products and technologies. We are cooperating with the best and most advanced labs in the world such as Centogene, TheragenEtex, Sequenom, MRC-Holland, 10x Genomics, Multiplicom-Agilent, Sophia genetics, DNA Genotek and many more. Pronto Diagnostics provides highly professional technical support. Its product specialists are dedicated to supporting the company's customers wherever they may be. For more details please contact our office at : info@prontodiagnostics.com

Vascular Graft Solutions (VGS), was founded in 2009 and is focusing on the development and commercialization of innovative solutions to improve the outcome of bypass surgeries. The company's leading product, the VEST (Venous External Scaffolding Technology), is a novel external mechanical support for autologous vein grafts, intended for improving vein graft longevity. Pre-clinical and clinical studies confirmed that by restraining wall tension and improving lumen uniformity, the VEST optimizes vein graft hemodynamics and mitigates vein graft disease. Randomized controlled trials and real-world data studies in Europe, demonstrated the biomechanical effect of external stenting, its statistically significant mitigation of vein graft disease, and improved clinical outcomes.

V-Wave Ltd. is a privately held company with offices in Israel and the US. The company is focused on developing percutaneous implantable devices for treating patients with chronic Heart Failure (HF). As a leading cause of death and hospitalization, HF continues to affect millions of people worldwide. V-Wave's vision is to help patients who remain with disabling symptoms or need hospitalization despite optimized medical treatment. V-Wave has developed a proprietary interatrial shunt intended to relieve symptoms, reduce hospitalization, increase exercise capacity and improve the overall quality of life. The original concept and development started in Israel with a talented team of engineers and medical scientists. The company's senior management has decades of experience successfully developing, clinically testing and bringing to market multiple implantable cardiovascular devices.